Sage Therapeutics, Inc. (NASDAQ:SAGE) saw unusually large options trading activity on Thursday. Stock investors bought 11,767 call options on the stock. This represents an increase of approximately Infinity compared to the average daily volume of 0 call options.

Sage Therapeutics (SAGE) opened at $96.04 on Friday. Sage Therapeutics has a one year low of $44.55 and a one year high of $98.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The business’s revenue was up .0% on a year-over-year basis. equities analysts forecast that Sage Therapeutics will post -7.34 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its position in shares of Sage Therapeutics by 1.1% in the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 62 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares in the last quarter. Keybank National Association OH lifted its position in shares of Sage Therapeutics by 10.6% in the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Sage Therapeutics by 19.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 497 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Sage Therapeutics by 0.9% in the second quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 552 shares in the last quarter.

Several equities research analysts have recently commented on the stock. Raymond James Financial, Inc. lifted their price target on shares of Sage Therapeutics to $109.00 and gave the stock a “buy” rating in a research report on Thursday. Chardan Capital upgraded shares of Sage Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $140.00 in a research report on Friday. Needham & Company LLC lifted their price target on shares of Sage Therapeutics from $86.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus lifted their price target on shares of Sage Therapeutics from $91.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Royal Bank of Canada lifted their price target on shares of Sage Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $99.86.

TRADEMARK VIOLATION WARNING: “Investors Buy Large Volume of Sage Therapeutics Call Options (SAGE)” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/investors-buy-large-volume-of-sage-therapeutics-call-options-sage/1696916.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.